Misplaced Pages

This is an old revision of this page, as edited by RussellBarkley (talk | contribs) at 17:28, 14 April 2014 (→NYT). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

NYT

"Dr. Barkley, who edits sluggish cognitive tempo’s Misplaced Pages page, declined a request to discuss his financial interests in the condition’s acceptance." http://www.nytimes.com/2014/04/12/health/idea-of-new-attention-disorder-spurs-research-and-debate.html You can tell us... `User:Fred Bauder Talk 09:08, 12 April 2014 (UTC)

First, let me say that Alan Schwarz's article is highly misleading both when he says that I refused to discuss my financial interests with him (I refused to be interviewed by him - period). It is precisely for this sort of highly biased writing in this and his previous articles on ADHD as well as his use of innuendo to distort or bias readers that I declined to be interviewed by him. It is most interesting that he then chooses to present this as a refusal to discuss a financial interest (about which he never asked me) rather than my outright refusal to be interviewed about anything with him. He also misrepresents my royalties from my rating scales claiming that I receive $131 for each rating scale when that is patently false. Guilford Press, the publisher of that scale, receives that income. I am paid a rather small percentage as a royalty out of that amount, as is typical of publishing books and scales in this field. I am pleased to note I was in good company as other researchers in this area also refused to be interviewed by this highly biased journalist.

Second, I fail to see any conflict of interest in my editing of this topic on SCT. Yes, I do speak for various pharmaceutical companies. This is widely known, is mentioned at the opening slide in any professional presentations I give, and is acknowledged in my peer reviewed publications. I also speak for a variety of universities, hospitals, associations, conferences, etc. each year for which I am customarily paid an honorarium. These, too, are acknowledged in all of my presentations. I also have written CE courses on the internet for which I receive a small royalty, none of which are on this topic. The fact that I occasionally speak at pharmaceutical company sponsored events is also posted at the various pharmaceutical company websites as part of their efforts at transparency and public disclosure of relationships with scientists. So any innuendo here that my compensated activities are somehow not disclosed is without merit. No pharmaceutical company has any medication on the market that is FDA approved for treating SCT. And that is because SCT is not an officially recognized clinical diagnosis (as yet) by the American Psychiatric Association or any other professional association to my knowledge. It is a relatively newly discovered condition that is receiving increasing research in psychology and psychiatry. So just where here is that financial conflict of interest represented? I am not paid by any drug company to speak on SCT and no such company has any product FDA-approved for it from which they derive any income. So there is no conflict of interest. I have received no payments for any of my articles on this topic either. Moreover, the fact that I receive a small royalty for my adult ADHD rating scale that contains a small set of items clinicians can begin to use to screen for this possible condition hardly rises to the level of a conflict of interest. The scale is marketed as an ADHD rating scale, of which there are many on the market as well. No one here has provided any evidence of a financial conflict of interest and that is because there is none. To imply otherwise here is to permeate a falsehood.

As a leading researcher and writer in this area, in editing this page I was attempting to convey the current status of this field, as was also reflected in my review of this topic published in the Journal of Abnormal Child Psychology in January. That is all that was intended here. Anyone else knowledgeable of this scientific literature is free to correct any statements I have made here about the condition, providing appropriate references for their editing, of course. But accusations of any conflicts of interest with my editing of this topic have no basis in fact. Russell A. Barkley, Ph.D.

Notice of Conflict of interest noticeboard discussion

This message is being sent to inform you that there is currently a discussion at Misplaced Pages:Conflict of interest/Noticeboard regarding a possible conflict of interest incident in which you may be involved. Thank you.